- Dr. Reddy’s Laboratories has launched its generic Semaglutide Injection in Canada, just days after receiving a Notice of Compliance (NOC) from Health Canada on April 28, 2026, highlighting the company’s readiness to rapidly supply the Canadian market
- Dr. Reddy’s became the first company to secure Health Canada approval for a generic semaglutide injection, with Canada also emerging as the first G7 country to grant market authorization for the product
- The once-weekly treatment for adults with type 2 diabetes is available in prefilled 2 mg and 4 mg pen formats, supporting multiple dosing options while aligning with current semaglutide treatment practices in Canada
- The launch builds on Dr. Reddy’s broader GLP-1 strategy and follows the recent introduction of semaglutide in India under the brand name Obeda, reinforcing the company’s focus on expanding access to affordable GLP-1 therapies across global markets
Takeaways
Dr. Reddy’s is using this Canada launch to cement itself as an early global player in generic GLP‑1 injectables, showing it can move from approval to market in days and supply at scale.
By being the first with a generic semaglutide injection in the first G7 country to allow it, and mirroring Ozempic‑like 2 mg and 4 mg pens, the company is positioned to pressure originator pricing, win tenders and formulary slots, and build on its Obeda launch in India as part of a broader push to make lower‑cost GLP‑1 therapies available across multiple markets.
Source: Businesswire
